ReviewJournal of thoracic disease2026
Bronchiectasis in the precision medicine era: pathogenesis and therapeutic advances.
Review in Journal of thoracic disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bronchiectasis is a highly heterogeneous chronic respiratory disease. This review aims to summarize recent advancements in pathogenesis and therapeutic strategies within the precision medicine framework, focusing on how individualized approaches to diagnosis and management are replacing conventional "one-size-fits-all" treatments to improve patient clinical outcomes. We synthesized high-level evidence from global registries, such as EMBARC and the BE-China National Prospective Registry, alongside findings from multi-omics research and recent clinical trials. The review evaluates quantifiable biomarkers for endotype-based stratification and assesses mechanism-oriented interventions, including novel targeted therapies and pathogen eradication strategies. Pathogenesis is now conceptualized through the "vicious vortex" model involving persistent infection, dysregulated inflammation, and structural damage. Specific biomarkers, including sputum neutrophil elastase (NE) activity and blood eosinophil counts, allow for the identification of distinct inflammatory endotypes. Notably, the August 2025 Food and Drug Administration (FDA) approval of brensocatib, a dipeptidyl peptidase 1 inhibitor, represents a major milestone in targeted therapy for non-cystic fibrosis bronchiectasis. Furthermore, advancements in understanding the airway resistome and managing multidrug-resistant Pseudomonas aeruginosa have provided robust tools for molecular classification and risk stratification in clinical practice. Bronchiectasis management has shifted from descriptive phenotyping to biomarker-driven endotyping. Transitioning toward mechanism-oriented interventions enables precise clinical decision-making, which is essential for modifying disease progression and reducing the global healthcare burden in the precision medicine era.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.